- Home
- MREO vs ELOX Comparison
MREO vs ELOX Comparison
Compare MREO & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MREO | ELOX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 41.0M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MREO | ELOX |
|---|---|---|
| Price | $0.31 | $17.40 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 4.9M | 53.4K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $5,184.20 | N/A |
| Revenue Next Year | $55.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $10.00 |
| 52 Week High | $2.37 | $19.96 |
Technical Indicators
Market Signals| Indicator | MREO | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 58.87 |
| Support Level | $0.28 | $10.74 |
| Resistance Level | $0.35 | $19.66 |
| Average True Range (ATR) | 0.03 | 2.14 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 40.48 | 71.32 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.